Daratumumab in Primary Antiphospholipid Syndrome - NCT05671757

The proportion of participants in the dose escalation phase with at least one Dose Limiting Toxicity (DLT), The proportion of participants with the following Grade 3 or higher adverse events (AEs) related to daratumumab, The proportion of Grade 2 or higher adverse event (AEs) related to daratumumab, (and 9 more...)